Ritodrine Production Cost Reports

The report provides a detailed analysis essential for establishing a Ritodrine production plant. It encompasses all critical aspects necessary for Ritodrine production, including the cost of Ritodrine production, Ritodrine plant cost, Ritodrine production costs, and the overall Ritodrine production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Ritodrine production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Ritodrine is a selective beta-2 adrenergic agonist that is used as a short-term tocolytic agent to suppress uncomplicated preterm labour. It is administered intravenously to relax uterine smooth muscle by elevating intracellular cyclic AMP levels. This stops myometrial contractions and delays delivery for 24 to 48 hours to enable maternal corticosteroid administration for foetal lung maturation or safe transfer to a tertiary care facility. Its effectiveness wanes after 72 hours due to tachyphylaxis, limiting routine long-term use in favour of magnesium sulfate or calcium channel blockers. Its common side effects include maternal tachycardia, palpitations, hand tremors, chest discomfort, tachypnoea, nausea, headache, hyperglycemia, hypotension, dizziness, flushing, and hypokalaemia.

The market for Ritodrine is driven by high global preterm birth rates. The demand for effective tocolytics in obstetric care, along with supportive healthcare policies promoting neonatal outcomes, boosts its market. The technological advancements in drug delivery systems, expanding clinical research validating short-term efficacy and growing incidence of risk factors like multiple pregnancies and maternal conditions make it a popular product.

The focus on sourcing from GMP, USDMF, and CEP-certified API manufacturers, purity levels of ≥98-99%, and certificates of analysis (COA) influences industrial Ritodrine procurement. The changes in raw material costs, regulatory compliance on IV infusions and oral tablets for hospital and institutional use and challenges from other competing agents like magnesium sulfate and nifedipine affect its sourcing.

Raw Material for Ritodrine Production

According to the Ritodrine production plant project report, the key raw materials used in the production of Ritodrine include 2-Amino-1-(4-hydroxyphenyl)propan-2-ol hydrochloride and 4-(2-chloroethyl)phenol or 4-(2-bromoethyl)phenol.

Production Process of Ritodrine

The extensive Ritodrine production cost report consists of the following major industrial production process:

1. By Condensation Reaction: The production process of Ritodrine involves condensation of 2-amino-1-(4-hydroxyphenyl)propan-2-ol hydrochloride with 4-(2-haloethyl)phenol. The reaction takes place in the presence of a KI catalyst and triethylamine as an acid binder in ethanol solvent. The reaction solvent is cooled to room temperature, filtering triethylamine hydrohalide, and acidifying the filtrate to pH 4–5 with HCl. The solvent is evaporated, and the product is recrystallised from n-hexane and ethyl acetate to get pure hydrochloride salt of Ritodrine.

Ritodrine has the molecular formula of C17H21NO3 and a molecular weight of 287.4 g/mol for the free base. Its hydrochloride salt has a molecular formula of C17H22ClNO3 and a molecular weight of around 323.8 g/mol. It is a white to off-white crystalline powder or resinous solid with a melting point between 88 and 90 degree Celsius. It has moderate lipophilicity with a logP value of 2.4 that facilitates membrane permeation. It has three phenolic hydroxyl groups, two hydrogen-bond donors, and three acceptors, yielding a topological polar surface area around 66 Ų. It has a basic secondary amine conducive to protonation and salt formation for enhanced aqueous solubility in parenteral applications.